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BACKGROUND: Aortic stenosis (AS) is highly prevalent in patients with atherosclerotic cardiovascular disease. Advanced glyca-
tion end products (AGEs) and the receptor for AGEs (RAGE) play a pivotal role for vascular calcification in atherosclerosis. We 
hypothesize that the AGEs–RAGE axis could also be involved in the pathophysiological mechanism of calcified AS.
METHODS AND RESULTS: A total of 54 patients with calcified AS who underwent aortic valve replacement were prospectively en-
rolled from 2014 to 2016 (mean age 75.3±7.7 years). Aortic valve specimens were obtained from 47 patients and 16 deceased 
control subjects without aortic valve disease (mean age 63.2±14.5 years). The valvular expression of RAGE was evaluated by 
immunohistochemistry. Serum levels of AGEs and soluble RAGE were measured in 50 patients with calcified AS and 70 age- 
matched and sex- matched control subjects without heart disease. The valvular RAGE expression in patients with calcified AS 
was higher than controls (P=0.004) and was significantly associated with a decreased ankle- brachial pressure index (P=0.007) 
and an increased intima- media thickness (P=0.026). RAGE and α–smooth muscle actin were coexpressed and were partially 
costained with osteocalcin and alkaline phosphatase. The serum levels of AGEs and soluble RAGE were significantly higher 
in the patients with calcified AS than in the controls (P=0.013 and P<0.001, respectively). Soluble RAGE (inversely) and use of 
aspirin were independently correlated with changes in left ventricular systolic function after aortic valve replacement (P=0.012 
and P=0.002, respectively).
CONCLUSIONS: Our present study suggests that RAGE may play a role in the pathogenesis of calcified AS, which is a prognostic 
marker in patients with AS after aortic valve replacement. 
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Aortic stenosis (AS) is one of the common cardio-vascular diseases (CVD) following coronary artery disease and essential hypertension.1 Although 
rheumatic fever was a main cause of AS until the 1970 
era, the prevalence and incidence of rheumatic fever 
were remarkably decreased.2 On the other hand, 
the number of patients with AS with a calcified aortic 
valve are rapidly increasing as a result of demographic 
aging.1 In developed countries, >25% of adults older 
than 65  years and almost 50% in those aged older 
than 85 years have some degree of AS.1,3 For a long 
time, calcified AS has been regarded as a passive 
degenerative disorder of the aortic valve.4 However, 
several recent studies have shown that AS has ac-
tive and multifaced processes during the progression 
of the calcification of valve leaflets.4 Histopathological 
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changes and pathogenetic pathways in calcified AS 
resemble those in atherosclerosis.5 Indeed, oxidized 
lipid retention, inflammatory reaction, and osteoblastic 
transformation of valve interstitial cells are involved in 
the pathogenesis of calcified AS.5
Advanced glycation end products (AGEs) are 
senescent macromolecular derivatives formed 
during the process of nonenzymatic Maillard reac-
tion.6 A cell surface receptor for AGEs (RAGE) is a 
signal- transducing receptor for AGEs that belongs to 
the immunoglobulin superfamily.7  There is a grow-
ing body of evidence that the AGEs–RAGE axis is 
implicated in various aging- related disorders, such 
as CVD, neurodegenerative disease, osteoporosis, 
and cancer growth and metastasis.8 Indeed, the en-
gagement of RAGE with AGEs elicits oxidative stress 
generation and evokes inflammatory, thrombotic, and 
fibrotic reactions in a variety of cells and therefore 
involved in atherosclerotic CVD.9 Moreover, soluble 
RAGE (sRAGE) was considered one of the prognos-
tic biomarkers for future cardiovascular events and 
death in humans.10 However, little is known about 
the pathological role of the AGEs–RAGE axis in cal-
cified AS. In this study, we addressed the issue of 
whether the AGEs–RAGE axis could contribute to the 
pathogenesis of calcified AS and if sRAGE may be 
a prognostic marker that predicted the improvement 
of cardiac function after aortic valve replacement in 
these patients. 
METHODS
The authors declare that all supporting results are 
available within the article.
Subjects
Patients with calcified AS who were hospitalized in 
Kurume University Hospital for aortic valve replace-
ment (AVR) were prospectively enrolled from July 
2014 to June 2016. Patients with Marfan’s syndrome, 
other known connective tissue diseases, or acute 
or chronic aortic dissection and those undergoing a 
re- replacement surgical procedure were excluded 
from the study. The severity of aortic valve disease 
was assessed by echocardiography according to 
the American Heart Association/American College of 
Cardiology Valvular Heart Disease Guideline with the 
aortic valve peak velocity ≥4.0 m/s or mean pressure 
gradient ≥40 mm Hg and aortic valve area ≤1.0 cm2 
(or aortic valve area index ≤0.6  cm2/m2).11 The study 
protocol was approved by the Ethical Committee for 
the Clinical Research of Kurume University. Written in-
formed consent was obtained from all patients. 
Clinical Variables
Medical history, including drug intake and smoking 
habit, was confirmed by a questionnaire. Blood pres-
sure was measured by an upright standard sphyg-
momanometer in the sitting position. Vigorous physical 
activity and smoking were avoided for at least 60 min-
utes before blood pressure and resting heart rate 
measurements. Intima- media thickness (IMT) of the 
common carotid artery was determined according 
to a method described previously.12 Ankle- brachial 
CLINICAL PERSPECTIVE
What Is New?
• Serum levels of advanced glycation end prod-
ucts and the receptor for advanced glycation 
end products were significantly higher in calci-
fied aortic stenosis patients than those in age-
matched and sex-matched controls.
• The soluble form of the receptor for advanced 
glycation end product was independently cor-
related with changes in left ventricular systolic 
function after aortic valve replacement.
• The valvular receptor for advanced glycation 
end products expression in calcified aortic ste-
nosis patients was significantly higher than that 
in controls and was associated with decreased 
ankle-brachial index and increased carotid in-
tima-media thickness. 
What Are the Clinical Implications?
• The receptor for advanced glycation end prod-
ucts may play a role in the pathogenesis of 
calcified aortic stenosis, which is a prognostic 
marker in patients with calcified aortic stenosis 
after surgical valve replacement. 
Nonstandard Abbreviations and Acronyms
∆LVEF change in left ventricular ejection fraction
ABI ankle-brachial pressure index
AGEs advanced glycation end products
ALP alkaline phosphatase
AS aortic stenosis
AVR aortic valve replacement
CVD cardiovascular disease
eGFR estimate glomerular filtration rate
IMT intima-media thickness
RAGE receptor for AGEs
SMCs smooth muscle cells
SMemb nonmuscle myosin heavy chain
sRAGE soluble RAGE
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systolic pressure index (ABI) was measured simulta-
neously using a validated automatic device (VP- 1000; 
Colin Corporation, Hayashi, Komaki City, Japan).13 
Patients underwent the ABI measurement after resting 
in the supine position for at least 5 minutes. A com-
prehensive 2- dimensional Doppler echocardiographic 
examination was performed on all patients using com-
mercially available ultrasound equipment (Vivid E90, GE 
Healthcare, USA) according to the American Society 
of Echocardiography guidelines. Aortic valve jet veloc-
ity was recorded in multiple transducer positions. The 
envelope of highest jet velocity signal was manually 
traced to obtain the peak velocity, mean pressure gra-
dient, and velocity time integral. The aortic valve area 
was measured by the continuity equation. Left ven-
tricular ejection fraction was obtained via the modified 
biplane Simpson method. Echocardiographic findings 
were blindly evaluated by 2 experienced sonographers. 
The European System for Cardiac Operative Risk 
Evaluation was used to calculate the surgical risk.14
Blood Biochemistry
Blood samples were drawn from the antecubital vein 
of 50 patients with calcified AS to determine lipid pro-
files (total cholesterol, high- density lipoprotein cho-
lesterol, and triglycerides), liver enzymes, uric acid, 
creatinine, C- reactive protein, calcium, phosphorus, 
and NT- proBNP (N- terminal pro- B- type natriuretic 
peptide).  Estimated glomerular filtration rate (eGFR) 
was calculated using the Modification of Diet in Renal 
Disease study equation modified with a Japanese co-
efficient.15 Serum levels of AGEs were measured using 
a competitive ELISA as described previously.16 Serum 
levels of sRAGE and sclerostin were determined with 
commercially available ELISA kits (R&D Systems, Inc., 
Minneapolis, MN).17 Other blood chemistry was meas-
ured with standard methods at a commercially availa-
ble laboratory (The Kyodo Igaku Laboratory, Fukuoka, 
Japan).18 The 70 age- matched, sex- matched, and 
eGFR- matched subjects without heart disease who 
visited our hospital for medical health checks were also 
enrolled as controls. Because renal function affects the 
serum levels of AGEs and sRAGE,19,20 we compared 
those values between the patients with AS and renal 
function (eGFR)- matched control subjects.
Histological Evaluation of Aortic Valves
Aortic valve specimens were obtained from the pa-
tients with calcified AS and autopsy control subjects. 
Antemortem echocardiography confirmed that the 
control subjects had no aortic valve disease. The 
valve specimens were fixed in neutral buffered for-
malin and then embedded in paraffin sections. The 
sections cut to 4 μm were used for light microscopy 
and Elastica van Gieson and immunohistochemical 
staining. RAGE, α–smooth muscle actin (αSMA), myo-
sin heavy chain’s isozyme (SM2), nonmuscle myosin 
heavy chain (SMemb), osteocalcin, and alkaline phos-
phatase (ALP) in calcified aortic valves were evalu-
ated with immunohistochemical or immunofluorescent 
staining.  The primary antibodies used in the present 
experiments were as follows: anti- RAGE (SC- 365154, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti- 
αSMA (55135- 1- AP, Proteintech, Rosemont, IL, USA), 
anti- osteocalcin (23418- 1- AP, Proteintech, Rosemont, 
IL, USA), anti- ALP (95462, Abcam, Cambridge, UK), 
anti- SMemb (7602, Yamasa Corporation, Chiba, 
Japan/204358, Abcam, Cambridge, UK), and anti-
 SM2 (7601, Yamasa Corporation, Chiba, Japan).   The 
nucleus was stained using Mayer’s hematoxylin and 
a fluorescent dye, TO-PRO3 (T3605, Thermo Fisher 
Scientific, Waltham, MA, USA).  Digital images were 
obtained by a microscope attached to the imaging 
software (KEYENCE BZ- 9000, KEYENCE, Japan). The 
positive rate of RAGE was defined using the following 
formula: (RAGE positive area÷specimen area)×100. 
Statistical Analysis
The values are presented as mean value±SD or median 
with the interquartile range. The Shapiro–Wilk test was 
performed to evaluate the assumption of normality. 
Statistical analysis was performed by means of appro-
priate parametric and nonparametric methods. Paired t 
test or chi- square test was conducted for comparisons 
between the calcified AS group and the control group. 
Correlations between AGEs and sRAGE and clinical 
variables were determined by linear regression analy-
sis. Serial echocardiographic variables are presented 
as mean (SE). Mixed effect models were employed to 
examine the effect of time in the echocardiographic var-
iables at baseline and follow- up. The overall time trend 
as well as pairwise comparisons were performed. The 
association of changes in the left ventricular ejection 
fraction from baseline to 7 days after AVR (ΔLVEF) with 
clinical parameters at baseline were also analyzed by 
linear regression analysis. To determine the independ-
ent correlates of the serum levels of AGEs, sRAGE, 
or ΔLVEF, multiple stepwise regression analyses were 
performed. All multivariate analyses were carried out 
by following process: Any risk factor with P<0.05 was 
entered into the multivariate model, and a stepwise 
procedure was employed to obtain the final model with 
the inclusion/exclusion criteria and a P value of 0.2. All 
statistical analyses were performed with the JMP Pro 
version 13.0 (SAS Institute Inc., Cary, NC, USA). 
RESULTS
A total of 54 patients with calcified AS (21 men 
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underwent AVR at our hospital were recruited. The 
clinical characteristics of the 54 patients with calci-
fied AS and 70 age- matched, sex- matched, and 
eGFR- matched control subjects are summarized in 
Table 1. The European System for Cardiac Operative 
Risk Evaluation was 7.85 (4.97–11.78), and the serum 
levels of NT- proBNP were 1100.5 (190.6–5253.9) 
pg/mL. The serum levels of AGEs and sRAGE were 
Table 1. Clinical Characteristics of Patients With Calcified AS and Control Subjects 
Variable Calcified AS (n=54) Control (n=70) P Value
Male, n (%) 21 (38.9) 39 (55.7) 0.063
Age, ±SD, y 75.3±7.7 75.4±3.9 0.905
Age range, y 60–93 71–84 ···
Body mass index, ±SD 22.6±3.9 23.0±2.8 0.517
NYHA functional class I/II/III/IV, n 6/36/12/0 ··· ···
Heart rate, ±SD, beats/min 69.5±13.4 64.6±12.3 0.039*
Systolic blood pressure, ±SD, mm Hg 121.0±23.9 139.6±19.3 <0.001*
Diastolic blood pressure, ±SD mm Hg 66.2±12.1 79.4±10.0 <0.001*
Estimate glomerular filtration rate, ±SD, mL/min/1.73 m2 56.5±32.5 63.8±10.7 0.082
EuroSCORE, median (IQR) 7.85 (4.97–11.78) ··· ···
C- reactive protein, median (IQR), mg/dL 0.09 (0.04–0.18) ··· ···
Calcium, median (IQR), mg/dL 9.0 (8.8–9.4) 9.1 (9.0–9.3) 0.335
Phosphorus, median (IQR), mg/dL 3.7 (3.2–4.2) 3.4 (3.0–3.8) 0.062
Sclerostin, median (IQR), pg/mL 199.0 (145.8–323.3) 437.3 (272.1–766.5) <0.001*
Total cholesterol, median (IQR), mg/dL 178.0 (154.0–198.5) 196.5 (177.0–221.3) <0.001*
High- density lipoprotein cholesterol, ±SD, mg/dL 56.8±13.3 56.0±12.9 0.766
Triglycerids, median (IQR), mg/dL 91.0 (76.0–133.0) 92.5 (71.8–123.5) 0.740
Glycated hemoglobin, median (IQR) 5.7 (5.5–6.1) 5.4 (5.2–5.7) 0.025*
NT- proBNP, median (IQR), pg/mL 1100.5 (190.6–5253.9) 92.9 (45.6–218.9) <0.001*
Advanced glycation end products, median (IQR), μg/mL 9.93 (8.31–12.19) 8.32 (7.10–10.06) 0.013*
sRAGE, median (IQR), pg/mL 1054.0 (640.3–1426.8) 679.8 (488.3–1021.7) <0.001*
Minimum ankle- brachial pressure index, ±SD 1.03±0.18 1.11±0.08 0.001*
Maximum IMT of carotid artery, median (IQR), mm 1.10 (0.98–1.43) 0.87 (0.81–0.98) <0.001*
Current smoking, n (%) 11 (20.4) 6 (8.6) 0.058
Hemodialysis, n (%) 9 (16.7) 0 <0.001*
Coronary artery disease, n (%) 20 (37.0) 0 <0.001*
Medications, n (%)
Statin use 26 (48.2) 20 (28.6) 0.025*
Aspirin use 15 (27.8) 13 (18.6) 0.224
Antihypertensive agents 42 (77.8) 36 (51.4) 0.003*
Oral hypoglycemic agents 9 (16.7) 7 (10.0) 0.272
Echocardiographic variables
Left ventricular ejection fraction, ±SD, % 62.0±11.1 70.4±5.2 <0.001*
Left ventricular diastolic diameter, median (IQR), mm 44.0 (41.7–49.0) 46.0 (42.9-49.0) 0.817
Left ventricular systolic diameter, median (IQR), mm 27.9 (25.8–31.0) 28.0 (24.9-30.0) 0.111
Interventricular septal wall thickness, mm 11.9±2.2 9.7±1.3 <0.001*
Posterior wall thickness, mm 11.7±1.9 9.9±1.1 <0.001*
Bicuspid valve, n (%) 12 (22.2) ··· ···
Aortic valve peak velocity, ±SD, m/s 4.5±1.0 ··· ···
Aortic valve peak pressure gradient, median (IQR), mm Hg 74.0 (60.1–108.2) ··· ···
Aortic valve mean pressure gradient, median (IQR), mm Hg 44.1 (31.8–60.7) ··· ···
Aortic valve area, median (IQR), cm2 0.73 (0.47–0.88) ··· ···
AS indicates aortic stenosis; EuroSCORE, European System for Cardiac Operative Risk Evaluation; IMT, intima- media thickness; NT- proBNP, N- terminal 
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significantly higher in the patients with calcified AS 
than in the controls. The serum levels of calcium 
or phosphorus were comparable between the 2 
groups, whereas the sclerostin levels in the patients 
with calcified AS were significantly lower than in the 
controls. The number of patients with calcified AS 
who received statin and antihypertensive agents 
was significantly higher than that of the control sub-
jects. When the calcified AS group was divided into 
2 groups, patients with statins and those without, the 
serum levels of C- reactive protein were significantly 
lower in the patients with statins compared with 
Table 2. Correlation of Clinical Variables With AGEs
Variable
Univariate Multivariate
r P Value Estimate SE P Value
Sex* 0.149 0.412 ··· ··· ···
Age 0.002 0.989 ··· ··· ···
Body mass index 0.344† 0.015† 0.028† 0.012† 0.034†
Heart rate 0.131 0.370 ··· ··· ···
Systolic blood pressure −0.078 0.596 ··· ··· ···
Diastolic blood pressure −0.052 0.722 ··· ··· ···
Estimate glomerular filtration rate 0.132 0.361 ··· ··· ···
C- reactive protein‡ −0.035 0.810 ··· ··· ···
Calcium‡ −0.039 0.787 ··· ··· ···
Phosphorus‡ −0.017 0.907 ··· ··· ···
Sclerostin‡ −0.033 0.822 ··· ··· ···
Total cholesterol 0.040 0.782 ··· ··· ···
High- density lipoprotein cholesterol −0.164 0.260 ··· ··· ···
Triglycerids‡ 0.162 0.266 ··· ··· ···
Glycated hemoglobin‡ 0.298† 0.038† 0.907 0.540 0.099
NT- proBNP‡ −0.186 0.200 ··· ··· ···
Receptor for AGEs‡ −0.061 0.676 ··· ··· ···
Minimum ankle- brachial pressure index 0.014 0.925 ··· ··· ···
Maximum IMT of carotid artery‡ −0.036 0.819 ··· ··· ···
Current smoking* −0.283 0.165 ··· ··· ···
Coronary artery disease* 0.316 0.624 ··· ··· ···
Medications ··· ··· ···
Statin use* 0.033 0.857 ··· ··· ···
Aspirin use* −0.147 0.451 ··· ··· ···
Antihypertensive agents* −0.016 0.943 ··· ··· ···
Oral hypoglycemic agents* 0.015 0.950 ··· ··· ···
Echocardiographic variables ··· ··· ···
Left ventricular ejection fraction 0.076 0.599 ··· ··· ···
Left ventricular diastolic diameter −0.084 0.560 ··· ··· ···
Left ventricular systolic diameter −0.105 0.469 ··· ··· ···
Interventricular septal wall thickness 0.137 0.344 ··· ··· ···
Posterior wall thickness 0.137 0.344 ··· ··· ···
Number of aortic valve 0.216 0.329 ··· ··· ···
Aortic valve peak velocity 0.091 0.528 ··· ··· ···
Aortic valve peak pressure gradient‡ 0.089 0.538 ··· ··· ···
Aortic valve mean pressure gradient‡ −0.004 0.978 ··· ··· ···
Aortic valve area‡ −0.048 0.742 ··· ··· ···
R2=0.175. AGEs indicates advanced glycation end products; IMT, intima- media thickness; and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
*Male=0, female=1 or no=0, yes=1.
†Statistically significant values.
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nonusers (0.05 mg/dL versus 0.11 mg/dL; P=0.013). 
In patients with calcified AS, the ABI levels were sig-
nificantly lower, whereas the IMT values were larger 
when compared with controls. Computed tomog-
raphy revealed that almost all patients had arterial 
calcification in a coronary artery and another vessel; 
75.9% of patients had a calcified lesion in the left cor-
onary artery and 64.8% in the right coronary artery. 
Calcification was also observed in 92.6% of patients 
in the aortic arch, 72.2% in the cervical arteries, 
77.8% in the abdominal aorta at the level of the renal 
artery, and 63.5% in the common femoral artery. 
Table 3. Correlation of Clinical Variables With sRAGE
Variable
Univariate Multivariate
r P Value Estimate SE P Value
Sex* −0.071 0.691 ··· ··· ···
Age −0.064 0.659 ··· ··· ···
Body mass index −0.412† 0.003† −0.035 0.017 0.052
Heart rate 0.131 0.370 ··· ··· ···
Systolic blood pressure −0.132 0.365 ··· ··· ···
Diastolic blood pressure −0.165 0.258 ··· ··· ···
Estimate glomerular filtration rate −0.699† <0.001† −0.008† 0.003† 0.013†
C- reactive protein‡ 0.188 0.192 ··· ··· ···
Calcium‡ 0.100 0.489 ··· ··· ···
Phosphorus‡ −0.088 0.543 ··· ··· ···
Sclerostin‡ 0.434† 0.002† 0.123 0.132 0.358
Total cholesterol −0.368† 0.009† −0.002 0.002 0.390
High- density lipoprotein cholesterol 0.045 0.761 ··· ··· ···
Triglycerids‡ −0.252 0.080 ··· ··· ···
Glycated hemoglobin‡ −0.386† 0.006† −0.666 0.780 0.398
NT- proBNP‡ 0.543† <0.001† 0.047 0.037 0.211
Advanced glycation end products‡ −0.061 0.676 ··· ··· ···
Minimum ankle- brachial pressure index 0.039 0.793 ··· ··· ···
Maximum IMT of carotid artery‡ −0.061 0.692 ··· ··· ···
Current smoking* 0.040 0.836 ··· ··· ···
Coronary artery disease* 0.093 0.523 ··· ··· ···
Medications ··· ··· ···
Statin use* 0.097 0.581 ··· ··· ···
Aspirin use* −0.051 0.804 ··· ··· ···
Antihypertensive agents* −0.053 0.795 ··· ··· ···
Oral hypoglycemic agents* −0.061 0.782 ··· ··· ···
Echocardiographic variables ··· ··· ···
Left ventricular ejection fraction 0.130 0.368 ··· ··· ···
Left ventricular diastolic diamete 0.019 0.894 ··· ··· ···
Left ventricular systolic diameter −0.108 0.457 ··· ··· ···
Interventricular septal wall thickness −0.017 0.906 ··· ··· ···
Posterior wall thickness 0.013 0.928 ··· ··· ···
Number of aortic valve 0.341 0.093 ··· ··· ···
Aortic valve peak velocity 0.126 0.385 ··· ··· ···
Aortic valve peak pressure gradient‡ 0.161 0.265 ··· ··· ···
Aortic valve mean pressure gradient‡ 0.203 0.166 ··· ··· ···
Aortic valve area‡ 0.005 0.975 ··· ··· ···
R2=0.586. IMT indicates intima- media thickness; NT- proBNP, N- terminal pro- B- type natriuretic peptide; and sRAGE, soluble receptor for advanced glycation 
end products.
*Male=0, female=1 or no=0, yes=1.
†Statistically significant values.




 http://ahajournals.org by on Septem
ber 30, 2020
J Am Heart Assoc. 2020;9:e015261. DOI: 10.1161/JAHA.119.015261 7
Saku et al RAGE and Aortic Stenosis
Correlation of Clinical Variables With 
Serum AGEs or sRAGE
We first investigated which clinical variables were in-
dependently correlated with serum levels of AGEs or 
sRAGE. In the univariate analysis, body mass index 
(P=0.015) and glycated hemoglobin (P=0.038) were sig-
nificantly correlated with serum levels of AGEs (Table 2). 
Because these significant parameters could be closely 
correlated with each other, multiple stepwise regression 
analysis was performed to determine the independent 
correlates of the serum levels of AGEs (Table 2). As a re-
sult, body mass index had an independent association 
with the serum levels of AGEs (P=0.034, R2=0.175). As 
shown in Table 3, univariate analysis revealed that body 
mass index (inversely), eGFR (inversely), sclerostin, total 
cholesterol (inversely), glycated hemoglobin (inversely), 
and NT- proBNP were associated with the serum lev-
els of sRAGE. Multiple stepwise regression analysis re-
vealed that eGFR was a sole independent correlate of 
serum sRAGE levels (Table 3; P=0.013, R2=0.586). 
Effects of AVR on Cardiac Function
Patients with calcified AS underwent isolated AVR and 
concomitant other cardiac surgeries. After surgical inter-
ventions, no serious perioperative adverse events were 
observed in our patients. Echocardiographic variables at 
baseline and follow- up are shown in Table 4. Seven days 
after AVR, left ventricular dimensions at the end- systolic 
and end- diastolic phases were significantly decreased 
from 45.6 (0.9) to 41.2 (0.9) mm (P<0.001) and from 29.4 
(0.8) to 26.3 (0.8) mm (P<0.001), respectively.  Left ventricu-
lar ejection fraction was significantly increased from 62.0% 
(1.4) at baseline to 66.1% (1.4) at 7 days after AVR (P=0.005) 
and to 70.1% (1.4) at 3 months after AVR (P<0.001). Similar 
to the left ventricular dimensions, the left atrial diameter 
also gradually decreased after AVR (Table 4).
Correlation of Baseline Clinical Variables 
With ∆LVEF
Next we examined the association of baseline clinical 
variables with ΔLVEF. As shown in Table 5, univariate 
analysis revealed that eGFR, phosphorus, total cho-
lesterol, sRAGE (inversely), and use of aspirin were sig-
nificantly correlated with ∆LVEF values. Phosphorus, 
sRAGE (inversely), and use of aspirin at baseline still 
remained significant and were independently corre-
lated with ∆LVEF values (R2=0.478). There was no sig-
nificant correlation between the serum levels of AGEs 
and ΔLVEF.
RAGE Expression in the Calcified Aortic 
Valve
Aortic valve specimens from 47 of the 54 patients 
with calcified AS (18 men and 29 women; mean age 
74.9±7.2 years) and 16 autopsy control subjects (11 
men and 5 women; mean age 63.2±14.5 years) were 
evaluated. Elastica van Gieson staining was per-
formed to confirm the structure of the calcified aor-
tic valve leaflet. The aortic valve has the following 3 
layers: fibrosa, spongiosa, and ventricularis.4 A large 
amount of calcium deposition was observed in the 
aortic side. RAGE was expressed in the calcified aor-
tic valves, which was expressed in all 3 layers, espe-
cially in the spongiosa and the ventricularis (Figure 1A). 
The least square mean of the valvular RAGE- positive 
area adjusted for age and sex by using an analysis 
of covariance was significantly higher in the patients 
with calcified AS than that in the controls (8.40% 
versus 2.31%; P=0.004) (Figure 1B) and was corre-
lated with ABI (inversely, r=−0.395, P=0.007) and IMT 
(r=0.356, P=0.026). In addition, the RAGE- positive 
area was significantly lower in patients who received 
statins than in those without (r=0.298, P=0.042). The 
calcified aortic valves contained smooth muscle cells 
(SMCs), which were mainly composed of SMemb- 
positive and SM2- positive cells, markers of synthetic 
and contractile SMCs, respectively21 (Figure  2A 
and 2B). An immunofluorescent study revealed that 
αSMA which is a marker of SMCs22 and RAGE were 
colocalized (Figure  3A and 3B). In addition, RAGE 
were costained with ALP, osteocalcin, and SMemb 
(Figure 3C) in calcified AS. 














Left atrial diameter, mm 42.5 (1.1) 40.2 (1.1) 0.004* 39.5 (1.1) <0.001* P<0.001*
Interventricular septal wall thickness, 
mm
11.9 (0.3) 11.9 (0.3) 0.801 11.3 (0.3) 0.042* P=0.050
Posterior wall thickness, mm 11.7 (0.3) 11.9 (0.3) 0.369 11.3 (0.3) 0.195 P=0.101
Left ventricular diastolic diameter, mm 45.6 (0.9) 41.2 (0.9) <0.001* 39.9 (0.9) <0.001* P<0.001*
Left ventricular systolic diameter, mm 29.4 (0.8) 26.3 (0.8) <0.001* 24.3 (0.8) <0.001* P<0.001*
Left ventricular ejection fraction, % 62.0 (1.4) 66.1 (1.4) 0.005* 70.1 (1.4) <0.001* P<0.001*
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DISCUSSION
The major findings of our study were that (1) serum lev-
els of AGE or sRAGE were significantly higher in pa-
tients with calcified AS than in control subjects, (2) low 
sRAGE values and the use of aspirin at baseline were 
independently correlated with ∆LVEF, (3) RAGE expres-
sion in calcified AS valves was significantly higher than 
in controls, and (4) RAGE and αSMA were coexpressed 
in AS tissues, parts of which were positively stained with 
markers of osteoblasts, such as ALP and osteocalcin.
Serum Levels of AGEs and sRAGE in 
Patients With Calcified AS 
Several cross- sectional and prospective studies 
have shown that the serum levels of AGEs were 
associated with CVD and become a predictor of 
future cardiovascular events and death.8,23–25 In ad-
dition, the serum levels of AGEs were associated 
with endothelial dysfunction, vascular inflammation, 
and sRAGE in patients high risk for CVD.8,10,16,17,26,27 
However, there is still some controversy about the 
Table 5. Correlation of Baseline Clinical Variables With the Change in Left Ventricular Ejection Fraction
Baseline Variable
Univariate Multivariate
r P Value Estimate SE P Value
Sex* −0.189 0.290 ··· ··· ···
Age −0.170 0.228 ··· ··· ···
Body mass index 0.095 0.502
Heart rate −0.028 0.846 ··· ··· ···
Systolic blood pressure 0.012 0.936 ··· ··· ···
Diastolic blood pressure 0.175 0.229 ··· ··· ···
Estimate glomerular filtration rate 0.323† 0.025† ··· ··· ···
C- reactive protein‡ 0.054 0.715 ··· ··· ···
Calcium‡ 0.033 0.823 ··· ··· ···
Phosphorus‡ 0.380† 0.008† 17.717† 5.964† 0.005†
Sclerostin‡ −0.168 0.253 ··· ··· ···
Total cholesterol 0.395† 0.006† 0.057 0.040 0.156
High- density lipoprotein cholesterol 0.093 0.535 ··· ··· ···
Triglycerids‡ 0.054 0.720 ··· ··· ···
Glycated hemoglobin‡ 0.043 0.775 ··· ··· ···
NT- proBNP‡ −0.170 0.254 ··· ··· ···
Advanced glycation end products‡ −0.039 0.790 ··· ··· ···
sRAGE‡ −0.431† 0.002† −5.549† 2.123† 0.012†
Minimum ankle- brachial pressure index 0.017 0.905 ··· ··· ···
Maximum IMT of carotid artery‡ 0.231 0.132 ··· ··· ···
Current smoking* 0.031 0.873 ··· ··· ···
Coronary artery disease* 0.139 0.324 ··· ··· ···
Medication, n*
Statin use* −0.232 0.175 ··· ··· ···
Aspirin use* 0.415† 0.025† −4.646† 1.374† 0.002†
Antihypertensive agents* −0.053 0.783 ··· ··· ···
Oral hypoglycemic agents* 0.324 0.142 ··· ··· ···
Echocardiographic variables
Number of aortic valve −0.289 0.134 ··· ··· ···
Aortic valve peak velocity 0.021 0.883 ··· ··· ···
Aortic valve peak pressure gradient‡ 0.027 0.850 ··· ··· ···
Aortic valve mean pressure gradient‡ 0.046 0.750 ··· ··· ···
Aortic valve area‡ −0.177 0.215 ··· ··· ···
R2=0.478. IMT indicates intima- media thickness; NT- proBNP, N- terminal pro- B- type natriuretic peptide; and sRAGE, soluble receptor for advanced glycation 
end products.
*Male=0, female=1 or no=0, yes=1.
†Statistically significant values.
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clinical significance of sRAGE in humans.10 Some 
researchers stated that sRAGE may protect against 
the AGEs- elicited vascular damage by acting as a 
decoy because exogenously administered sRAGE 
may capture and eliminate circulating AGEs.28 On 
the contrary, other researchers have the opposite 
opinion. They demonstrated that sRAGE levels were 
positively associated with serum levels of AGEs, in-
flammatory biomarkers, and CVD in both diabetic 
and nondiabetic patients; therefore, it could reflect 
tissue RAGE expression.8,10,29–32 In support of the 
latter speculation, several prospective studies have 
recently shown that higher serum levels of sRAGE 
could predict future cardiovascular events and 
death.33,34 In this study, serum levels of AGEs and 
sRAGE and valvular RAGE expression were signifi-
cantly higher in patients with calcified AS compared 
with controls. Furthermore, we found that low sRAGE 
at baseline was independently associated with the 
improvement of the left ventricular ejection fraction 
after aortic valve replacement. Because early post-
operative improvement of the left ventricular ejec-
tion fraction was associated with a significant relief 
of heart failure symptoms and favorable prognosis,35 
our present findings suggest that sRAGE may be a 
marker for AGEs–RAGE axis activation and identify 
patients with AS who may benefit from valve replace-
ment surgery.
Phenotypic Change of SMCs Within 
Calcified Aortic Valves
Transdifferentiation of valvular interstitial cells into os-
teoblastic and myofibroblastic cells is supposed to play 
a role in the development and progression of valvular 
calcification in AS.4,5 Indeed, the expression levels of 
markers of myofibroblast cells and SMCs in calcified 
aortic valves are correlated to the severity of calcifica-
tion in AS.22 In the initial and early phase of atheroscle-
rosis, vascular SMCs undergo a phenotypic change 
from contractile type to synthetic type in response to a 
Figure 1. Expression of RAGE in calcified AS valves.
A, Expression of RAGE in calcified AS valves. *Left ventricle side. 
B, RAGE positive area (percentage) in calcified AS and controls 
(P=0.014). AS indicates aortic stenosis; Ca, calcification; and 
RAGE, receptor for advanced glycation end products.
Figure 2. Expression of SMCs in calcified AS valves.
A and B, Calcified aortic valve contained SMCs, which were mainly composed of SMemb- positive or SM2- positive cells (n=6). *Left 
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variety of atherogenic stimuli, such as oxidative stress 
shear stress and inflammatory, cytokine, and growth 
factors.36  Our present study revealed that SMemb- 
positive SMCs, a marker of the synthetic SMCs type, 
were rich in the calcified aortic valves. Therefore, the 
phenotypic change of SMCs may also be involved in 
calcified AS.
RAGE Expression in Calcified Aortic 
Valves and Atherosclerosis
Carotid artery IMT and ABI are representative surrogate 
markers that could predict future atherosclerotic car-
diovascular events in humans.37,38 In the present study, 
valvular RAGE expression in patients with calcified AS 
was correlated with low ABI and high carotid artery 
IMT values. In addition, the valvular RAGE expression 
was significantly lower in patients taking statins than 
those without. Besides lowering low- density lipoprotein 
cholesterol levels, statins have been shown to exhibit 
anti- inflammatory properties on vascular wall cells.39 
Indeed, the serum levels of C- reactive protein in pa-
tients with statins were significantly lower than those 
without statins (P=0.013). Because statins delayed the 
progression of AS,40 statins may have protective effects 
against AS partly via the suppression of the AGEs–
RAGE axis.
Osteogenic Differentiation of SMCs in 
Calcified Aortic Valves Via RAGE
Engagement of RAGE with AGEs evokes inflammatory 
and oxidative stress reactions and could promote the 
osteoblastic differentiation of SMCs, as evidence by 
ALP, osteopontin, and osteocalcin overexpression.41,42 
Furthermore, RAGE activation in aortic valves has been 
shown to stimulate the production of proinflammatory 
cytokines and promote the progression of aortic valve 
calcification.43,44 RAGE- deficient mice were resistant 
to aortic valve stenosis while on a high- fat diet.45 In our 
study, RAGE and αSMA were coexpressed in calcified 
aortic valves, part of which were costained with ALP 
and osteocalcin, markers of osteoblasts as well as 
SMemb. Taken together, although our present study 
showed a correlation, not causation, activation of the 
AGEs–RAGE axis may contribute to the development 
and progression of calcified AS.
Limitations
There are some limitations in this study. First, this was a 
relatively small study with short observational periods. 
We could not quantify the immunofluorescence im-
ages because of a lack of samples. Second, although 
age- matched, sex- matched, and eGFR- matched 
subjects without organic heart disease were used as 
Figure 3. αSMA and RAGE were colocalized, part of which were costained with ALP, osteocalcin, and SMemb in calcified 
aortic stenosis valves.
A and B, Immunofluorescence imaging of αSMA and RAGE in aortic stenosis patients (n=6) and controls (n=2). C, Immunofluorescent 
staining of ALP (n=5), osteocalcin (n=5), and SMemb (n=2) in aortic stenosis valves. TOPRO- 3 was used for nuclear staining. αSMA 
indicates α–smooth muscle actin; ALP, alkaline phosphatase; RAGE, receptor for advanced glycation end products; and SMemb, 
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controls in the present study, many unadjusted factors 
could confound the present findings. Third, because 
we could not measure the calcium score, we did not 
clarify whether the levels of calcification in the valves 
were consistent among patients. Fourth, the post-
operative levels of sRAGE were not measured in this 
study. Further longitudinal studies are needed to clarify 
whether the suppression of the AGEs–RAGE axis by 
statins could actually slow down the process of AS and 
improve survival in these patients.
CONCLUSIONS
Our present study suggests that RAGE may play a role 
in the pathogenesis of calcified AS, which is a prog-
nostic marker in patients with calcified AS after surgical 
valve replacement. 
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